Navigation Links
Eurocine Vaccines Strengthens the Organization for Further Development
Date:4/7/2017

STOCKHOLM, April 7, 2017 /PRNewswire/ -- Eurocine Vaccines strengthens the organization with necessary competence, not only to prepare for further development of its first product, the nasal influenza vaccine candidate Immunose™ FLU, but also for further development of a pipeline of other vaccines based on the patented technology platform Endocine™.

"In parallel with finalizing the analyses and evaluation of the current study, we now prepare for the next steps of development. Reinforcing the organization with Sandra Jeldes Granstrand, a senior and experienced Project Leader of CMC[1], supports our ambitious strategy and rapid development ahead", said CSO Anna-Karin Maltais.

Simultaneously, CSO Anna-Karin Maltais is appointed Vice President Research and Development.

"This emphasizes our positive ambitions as we continue building value", said CEO Hans Arwidsson and continued "Ensuring that the next influenza season can be well used for further development, opens for a shorter way to market, to the benefit of patients and partners."

Results from the ongoing clinical study are expected in June/July 2017.

More information about the study can be found at www.clinicaltrials.gov.

[1] Chemistry Manufacturing and Control

CONTACT:
CEO of Eurocine Vaccines AB
hans.arwidsson@eurocine-vaccines.com  
+46-70-634-0171

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/eurocine-vaccines/r/eurocine-vaccines-strengthens-the-organization-for-further-development,c2235009

The following files are available for download:

http://mb.cision.com/Main/11552/2235009/654837.pdf

Se news release

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/eurocine-vaccines-strengthens-the-organization-for-further-development-300436536.html


'/>"/>
SOURCE Eurocine Vaccines
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Animal Vaccines Market Expected to Reach $9,159 Million by 2022 - Allied Market Research
2. New Access to Vaccines Index Reveals First Landscape of Vaccine Company Actions to Improve Immunisation Coverage
3. Immunomodulators Market Analysis By Product (Immunosuppressant, Immunostimulants, Vaccines, Antibodies), By Application (Oncology, Respiratory, HIV), By Region, And Segment Forecasts, 2014 - 2025
4. Global Influenza Vaccines - World Industry Market Outlook 2017-2027
5. Research and Markets - Global Travel Vaccines Market 2016-2020: Market Growth at CAGR of 6.83% - Growing Demand Among Travelers / Additional Age Group Approval / Inclusion in NIP
6. Human Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
7. Global Influenza Vaccines Market and Forecast to 2021: North America Accounted for 50% of the $5 Billion Market in 2015 - Research and Markets
8. Research and Markets - Global H1N1 Vaccines Market Analysis 2016-2025 - Trends, Technologies & Opportunities Report 2016-2025 - Vendors: Novartis, Zydus Cadila, Merck
9. Vaccines a 28 Billion-Dollar Market, Kalorama Information Study Finds
10. Kalorama: After Allergan Merger Halt, Vaccines a Focus for Pfizer
11. Profectus and Vyriad Form Global Collaboration to Develop Oncolytic Recombinant VSV (rVSV) Vaccines for Cancer Immunotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... Fix Inc. (" Fortuna "), a private, clinical-stage biotech ... need for embryonic and fetal stem cells by using direct ... Fortuna announced today the launch of its Scientific ... PhD; Father Kevin FitzGerald , S.J., PhD; Col. (R) ... Giordano , PhD. "We are excited and honored ...
(Date:5/4/2017)... , May 4, 2017  DarioHealth Corp. (NASDAQ: ... health and big data solutions, today announced that it ... Company, and STI Technologies Limited to lower diabetes healthcare ... Through STI,s innoviCares card, which is available throughout all ... DarioHealth customers will be eligible for additional savings when ...
(Date:5/3/2017)... ROCKVILLE, Md. , May 3, 2017 /PRNewswire/ ... revenue growth of nine percent next year and ... solid organ and hematopoietic stem cell (HSCT) or ... and donor. Molecular testing technologies are well-suited for this ... healthcare-only market research publisher Kalorama Information. The various ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... ... Axiad IDS , a leading provider of trusted identities for enterprise, ... a “Top 25 Cybersecurity Companies 2017.” Axiad IDS received this honor in ... address potential cybersecurity threats before they happen. The annual list of top ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... the pharmaceutical and medical device sectors, today announced the winners of its 3rd ... Entrepreneurs) represent the most influential people in the healthcare industry today. , Out ...
(Date:5/23/2017)... ... May 23, 2017 , ... New England Journal Of Medicine Confirms Viability of ... Response”, -The Rory Staunton Foundation Calls on Health & Human Services, Tom Price to ... ( http://www.rorystauntonfoundation.org ) today reported on a new study released on May 21, 2017 ...
(Date:5/23/2017)... ... May 23, 2017 , ... The National ... is pleased to announce the organization’s Certified Strength Coach credential has earned accreditation ... Coach (CSC) program validates the competency of qualified candidates for jobs in the ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... Reconstructive Surgeon Dr. Kevin Sadati, is pleased to announce a new treatment option ... and elastin in their face, neck, and body through a virtually pain-free, non-surgical ...
Breaking Medicine News(10 mins):